This may be due to the inclusion of patients with pure adenocarcinoma, a greater number of non-smokers, a higher EGFR mutation rate among the Taiwanese patients, and the integration of EGFR-TKI treatment. The gene discussed is EGFR; the disease is adenocarcinoma.